Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Human Alpha 1 Proteinase Inhibitor
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : $7.0 million
Deal Type : Licensing Agreement
Kamada Announces Amendment to GLASSIA® License Agreement with Takeda
Details : Following the completion of the transition of GLASSIA manufacturing, Kamada will transfer the product’s us biologics license application (BLA) to takeda.
Brand Name : Glassia
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 07, 2021
Lead Product(s) : Human Alpha 1 Proteinase Inhibitor
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : $7.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?